Crucell (CRXL)

[SittingDuck]

Crucell Announces Acquisition of SBL Vaccin AB and Offering of New Ordinary Shares
Leiden, The Netherlands, November 21, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has signed an agreement for the acquisition of Stockholm-based SBL Vaccin AB (SBL) from 3i and SEB for a total consideration of €39.4 million in cash. It is expected that the transaction will be completed on Thursday, November 23, 2006.

Crucell intends to raise €80 million through the issue of new ordinary shares. The proceeds will be used to fund the acquisition of SBL, the acquisition of Berna Products Corporation on October 2, 2006 and repayment of outstanding debt relating to Berna Biotech AG.